Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/candesartan cilexetil - HK inno.N

Next Previous
Search
Drug Profile

Amlodipine/candesartan cilexetil - HK inno.N

Alternative Names: Amlodipine besylate/candesartan cilexetil; CJ 30059; Machkhan

Latest Information Update: 30 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ HealthCare
  • Developer HK inno.N
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension
  • No development reported Angina pectoris

Most Recent Events

  • 18 Jun 2020 CJ HealthCare is now called HK inno.N
  • 05 Sep 2017 No development reported - Phase-I for Angina pectoris (In volunteers) in South Korea (PO)
  • 31 Dec 2016 Launched for Essential hypertension in South Korea (PO) (CJ HealthCare website, September 2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top